Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) CFO Tighe Reardon sold 822,721 shares of the stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $54.75, for a total value of $45,043,974.75. Following the sale, the chief financial officer now directly owns 633,673 shares of […]
Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) major shareholder Ventures Xi L.P. Avalon sold 677,279 shares of Janux Therapeutics stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $54.75, for a total value of $37,081,025.25. Following the transaction, the insider now directly owns 3,271,216 shares of […]
Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) major shareholder Ventures Xi L.P. Avalon sold 677,279 shares of Janux Therapeutics stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $54.75, for a total value of $37,081,025.25. Following the transaction, the insider now directly owns 3,271,216 shares of […]
Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) Director Jay Lichter sold 1,500,000 shares of the business’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $54.75, for a total transaction of $82,125,000.00. Following the sale, the director now directly owns 633,673 shares of the company’s stock, […]
Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) – Stock analysts at HC Wainwright lowered their Q2 2024 EPS estimates for shares of Janux Therapeutics in a report issued on Monday, May 13th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.38) per share for the quarter, down from their previous estimate […]